Nano Dimension to merge with Infinite Epigenetics, entering AI-powered health diagnostics market.

Nano Dimension has signed a term sheet to merge with Infinite Epigenetics, an AI-driven preventive health and diagnostics company focused on epigenetics. This move shifts Nano Dimension's focus from digital manufacturing to a high-growth healthcare AI sector, targeting a $90 billion U.S. clinical diagnostics market. The combined company will operate under the Infinite Epigenetics name and trade on Nasdaq, aiming to leverage proprietary biological AI to detect chronic diseases earlier. Existing Nano shareholders will retain significant ownership, with the deal valued at $890 million and expected to provide over $400 million in cash at closing to fuel growth.